Gilead Sciences Inc. Partners with Center for Translational Antiviral Research to Test Oral Remdesivir Variant
Gilead Sciences Inc. Partners with Center for Translational Antiviral Research to Test Oral Remdesivir Variant
To better reach outpatients early after a COVID-19, infection, Gilead Sciences Inc. has partnered with researchers in Georgia State University’s Center for Translational Antiviral Research to test a modified version of remdesivir that can be taken orally.